Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loc-R01 lenalidomide and ibrutinib with R-MPV for newly diagnosed primary central nervous system lymphoma
2024-515331-30-00Phase 2Authorised
- Sponsor
- Institut Curie
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lenalidomide, ibrutinib, rituximab, methotrexate, procarbazine and 1 more in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Institut Curie. Planned start Oct 2020; status: authorised.
02
Drugs
lenalidomideibrutinibrituximabmethotrexateprocarbazine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2024-515331-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515331-30-00.